Seraxis Announces Closing of Second VC Tranche and Successful Completion of Preclinical Studies of Pancreatic Organoids From Seraxis’ Novel Pancreas-Derived Stem Cells
Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients

Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients

September 20, 2023 Sam M 0

Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients

Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients

The health IT vendor partnership extends Interlace Health’s forms automation and electronic signature capture capabilities to MEDITECH Expanse EHR customers

Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients
MEDITECH Alliance

Interlace Health is a MEDITECH Alliance Innovator Partner

As a member of the MEDITECH Alliance Innovator Program, Interlace Health delivers proven, successful, and interoperable forms automation, check printing, and eSignature solutions to health systems using MEDITECH Expanse.

Interlace Health works in conjunction with MEDITECH Expanse to enable paperless consenting. Providers can easily and efficiently collect eSignatures from patients and witnesses at the bedside, during clinic visits, and at registration. MEDITECH customers have transformed their eConsent, Patient Intake, Check Printing, and Forms-on-Demand processes with Interlace Health, in the acute, ambulatory, and post-acute care settings.

“We are happy to welcome Interlace to the Alliance,” said James Merlin, Chief Business Development Officer at MEDITECH. “We look forward to customers realizing the benefits of a standardized approach to delivering forms automation, check printing, and eSignature solutions through our partnership.”

MEDITECH Alliance is an ecosystem of healthcare technology companies that effectively collaborate with MEDITECH and complement, enhance, or extend MEDITECH Expanse. The MEDITECH Alliance Innovator Program is an invitation-only program consisting of MEDITECH partners with validated solution integration for specific use cases within Expanse. Innovator solutions are certified with MEDITECH’s technical and application teams. As a result, these solutions will be more deeply integrated in the MEDITECH EHR, with accelerated, seamless deployment based on standardized best practices and shared implementation guides.

As an Innovator, Interlace Health provides leading eForm, check printing, and eSignature solutions to MEDITECH Expanse customers.

“Our partnership and deep integration capabilities with MEDITECH have always been a key component to our success, as well as that of our shared 400+ hospital clients. As an Innovator in the MEDITECH Alliance, we look forward to helping MEDITECH Expanse organizations eliminate remaining paper processes to further drive cost and time savings, improve experiences, and ensure compliance,” said Allison Reichenbach, President at Interlace Health.

Interlace Health looks forward to presenting at MEDITECH LIVE September 20-22, in Foxborough, MA. Learn more about connecting with Interlace Health at MEDITECH LIVE: https://interlacehealth.com/meditech-live-2023/

About Interlace Health

Interlace Health (the next generation of FormFast) delivers forms automation and eSignature solutions that are more scalable and cost-effective than your EHR. For more than 30 years, Interlace Health has pioneered eForms, eSignature, and workflow technology.

By enabling seamless data capture and information exchange among providers, staff, and patients, Interlace Health solves many of healthcare’s central challenges through process transformation. The result for its clients is reduced costs, increased collections, uplifted patient experiences, improved operational efficiency, and enhanced support of an organization’s integration strategy. Interlace Health’s platform enables several solutions that are accessible by clinicians and patients inside and outside the walls of the healthcare system. These include Forms on Demand, Patient Intake, and eConsent. To learn more, visit www.interlacehealth.com.

Contact Information:

Lauren Ziegler

Director, Marketing Communications

[email protected]

314-677-3765

Original Source:

Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients

The post Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients first appeared on Enrose Magazine.

The post Interlace Health Joins MEDITECH Alliance Innovator Program to Deliver Leading eForm Solutions to Expanse Clients appeared first on IGP Beauty.

Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process

Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process

September 20, 2023 Sam M 0

Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process

Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process

Professional Hospital Guaynabo (PHG) issued the following statement in light of the recent ruling by Judge Alfonso Martínez Piovanetti of the Court of First Instance of Puerto Rico, ordering MSO of Puerto Rico, a subsidiary of Elevance Health, to uphold its Hospital Service Agreement (HSA) with PHG throughout the ongoing arbitration process.

“The Court’s decision to uphold the existing partnership between Professional Hospital Guaynabo and MSO of Puerto Rico not only guarantees that our patients will continue to benefit from world-class medical care provided by trusted physicians but also ensures network adequacy and compliance with CMS standards,” stated Administrator Giancarlo Valentín, PhD, MHSA.

Background:

PHG, situated in the Municipality of Guaynabo, serves as the municipality’s sole general hospital, catering to the needs of over 89,000 residents. Providing round-the-clock emergency room services, PHG annually serves 33,000 patients. The hospital achieved Hero Hospital status during both the COVID-19 pandemic and Hurricane Maria, known for its medical expertise in vascular diseases and the performance of cutting-edge surgeries, making it a healthcare cornerstone in Puerto Rico.

Contact Information:

Giancarlo Valentin

[email protected]

Original Source:

Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process

Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process

The post Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process first appeared on Enrose Magazine.

The post Significant Court Decision Safeguards Professional Hospital Guaynabo’s Contractual Relationship With MSO of Puerto Rico Amidst Ongoing Arbitration Process appeared first on IGP Beauty.

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group

September 14, 2023 Sam M 0

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group

Unveiling the Potential Breakthrough – Activating Stem Cells to Delay and Reduce Dementia and Depression Risk

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group
Dr. Lee & Dr. Lin

Dr. Jia-Fu Lee from Tzu Chi Hospital & Dr. Chai-Ching Lin from Power-Stem Biomedical

Alzheimer’s disease and dementia severity in the United States is escalating, posing a growing public health crisis. With an aging population, millions are affected by these devastating conditions. The ratio of Alzheimer’s patients in the 65+ demographic has reached 1 in 9 based on the study by the American CDC (Center of Disease Control and Prevention), highlighting the urgent need for research, care improvements, and increased awareness to address their profound social, economic, and emotional impact.

In response to World Alzheimer’s Month, Taipei Tzu Chi Hospital and Power-Stem Biomedical Group (Parent Company of Beauty-Stem Biomedical) jointly held a symposium. Dr. Jia-Fu Lee from Tzu Chi Hospital and Dr. Chai-Ching Lin, the President of Power-Stem Biomedical, discussed the testing data from a human trial program. 

“Our momentous achievement has arrived!” declared Dr. Chai-Ching Lin, President, Power-Stem Biomedical. “We proudly introduce the world’s first stem cell supplement, underwent by rigorous clinical trials and scientific validation. This marks an exciting breakthrough in regenerative supplements, a new chapter in our commitment to advancing science and improving lives.”

They assessed brain degeneration by measuring Alzheimer’s Disease Risk Index (ADRI) and CD34+ hematopoietic stem cell levels through scientific and quantitative blood tests after the usage of CD34 NU-Signals. It has been observed that when individuals start to notice memory and cognitive decline, the number of stem cells in their bodies also decreases significantly. Clinically, early detection and prevention are possible through a healthy diet, quality sleep, and regular exercise. And refer to the study, activating autologous stem cells through stem cell nutrients can significantly reduce value of ADRI risk index and increase stem cell count.

Dr. Lee from Taipei Tzu Chi Hospital’s Dementia Care Center stated that by analyzing brain waves with ADRI technology, and evaluating the risk of dementia through blood tests, it is possible to objectively detect the levels of depression and dementia risk. Through personalized regenerative supplement, mental well-being, exercise, and quality sleep, one can regain cardiovascular and brain health vitality.

Dr. Lin has been researching the field of stem cells for many years, and she has contributed significantly to stem cell nutrition. She has published multiple patents, scientific journals, and books. Dr. Lin emphasizes the importance of paying attention to one’s “Health Deposit” after the age of 40. Therefore, tracking CD34+ hematopoietic stem cells, NK natural killer cells, and ADRI annually are crucial life indicators to better understand one’s hematopoietic capacity, immune system, and self-healing ability.

Dr. Lee added that, especially in the case of ADRI values, they should be improved to reach a score of 0. Maintaining a happy and contented mind is essential for effectively staying away from depression and dementia.

Contact Information:

Kaihsiang Lee

Marketing Manger

[email protected]

888-341-7505

Related Files
Beauty-Stem US Health Deposit.pdf
CD34 Nu-Signals DM.pdf

Original Source:

CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group

The post CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group first appeared on Enrose Magazine.

The post CD34 NU-Signals and Alzheimer’s Disease Human Trials Presentation With Tzu Chi Hospital and Beauty-Stem Biomedical, Subsidiary of Power-Stem Biomedical Group appeared first on IGP Beauty.